Form 4: Dyne Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, sold 2,856 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,856 shares of common stock on November 18, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units granted on November 15, 2023.
• The shares were sold at a weighted average price of $28.2, with individual transactions ranging from $28.00 to $28.60.
• Following the transaction, Beskrovnaya beneficially owns 137,519 shares, which includes 104,205 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The sale was conducted under a pre-arranged plan (Rule 10b5-1), which is a standard practice to avoid accusations of insider trading.
• The price range of $28.00 to $28.60 is within the expected range for a stock sale of this type.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Dyne Therapeutics, Oxana Beskrovnaya, stock sale, restricted stock units, tax obligations, insider trading, Form 4